Based on the reduction of azo groups by azoreductase within the hypoxic tumor microenvironment, we have developed a hypoxia-activated self-immolative prodrug containing a HIF-1α inhibitor and a HDAC inhibitor for the first time. This evidence concerns the gene HIF1A and neoplasm.